[Skip to Content]
[Skip to Content Landing]
Citations 0
The World in Medicine
August 19, 2009

River Blindness Trial

JAMA. 2009;302(7):732. doi:10.1001/jama.2009.1158

A newly launched phase 3 clinical trial will investigate whether moxidectin, a drug currently used to treat parasites in animals, can speed the elimination of onchocerciasis, or river blindness, one of the leading causes of blindness across Africa (http://apps.who.int/tdr/news-events/news/pdf/moxidectin-press-release.pdf). The Special Program for Research and Training in Tropical Diseases, which is administered by the World Health Organization, will conduct the trial with African investigators and institutions and enroll 1500 individuals at 4 sites in Ghana, Liberia, and the Democratic Republic of the Congo.

First Page Preview View Large
First page PDF preview
First page PDF preview
×